Pharma: Page 7
-
An enduring COVID mystery: Why some do fine and others die
The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.
By Alexandra Pecci • Jan. 17, 2024 -
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
By Kelly Bilodeau • Jan. 16, 2024 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Opinion
Pharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
4 big FDA approval dates to watch in 2024
Following a year where the FDA approved 55 new drugs, the 2024 PDUFA calendar is set with a number of potentially buzzy approvals.
By Alexandra Pecci • Jan. 12, 2024 -
Opinion // Year in Preview
PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
By Meagan Parrish • Jan. 11, 2024 -
Believe the hype? Mixed signals from AI’s impact on drug development
Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.
By Kelly Bilodeau • Jan. 10, 2024 -
Opinion // Year in Preview
PharmaVoice’s Crystal Ball: Perspectives on the financial future
Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.
By Meagan Parrish • Jan. 9, 2024 -
Regulatory twists and turns are coming for biopharma in 2024
New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.
By Kelly Bilodeau • Jan. 8, 2024 -
How J&J is tackling a ‘secondary pandemic’ in the Black community
J&J is leading a grassroots effort to improve mental health access and care.
By Alexandra Pecci • Jan. 8, 2024 -
In the post-pandemic era, three players still dominate the infectious disease market
While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.
By Alexandra Pecci • Jan. 5, 2024 -
Alzheimer’s research is hot, but successful patient recruitment will determine its future
Key strategies for bringing more patients into the clinical trial fold.
By Kelly Bilodeau • Jan. 4, 2024 -
Pharma’s financial market will be a tale of two cities in 2024
What can the industry expect in 2024? Some bright spots, a few bumps and “immaculate disinflation.”
By Kelly Bilodeau • Jan. 4, 2024 -
Why J&J rebranded its iconic logo
J&J’s refreshed identity provides insight into how and why pharma companies give themselves a makeover.
By Alexandra Pecci • Jan. 3, 2024 -
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
Biopharma’s FTC headache deepens with guideline shifts years in the making
Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.
By Michael Gibney • Dec. 21, 2023 -
What are pharma’s next blockbusters?
In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.
By Kelly Bilodeau • Dec. 20, 2023 -
5 noteworthy pharma AI investments in 2023
The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.
By Alexandra Pecci • Dec. 19, 2023 -
Shutterstock ID: 1752872030
Sponsored by OracleTrends shaping the pharmaceutical industry in 2024
Advancements in cloud and AI technology will transform clinical trial efficiency and engagement.
By Seema Verma, SVP and GM, Oracle Life Sciences • Dec. 18, 2023 -
Study suggests PBMs are gaming pharmacy system to overcharge for drugs
Markups for generics can be as high as 7,000%, the researchers said.
By Alexandra Pecci • Dec. 15, 2023 -
Q&A
The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
By Michael Gibney • Dec. 14, 2023 -
Q&A
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
By Meagan Parrish • Dec. 13, 2023 -
What’s being done to prepare for the next pandemic?
Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.
By Kelly Bilodeau • Dec. 13, 2023 -
Q&A
Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
By Michael Gibney • Dec. 12, 2023 -
Q&A // First 90 Days
Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
By Alexandra Pecci • Dec. 11, 2023 -
Oncology drugmakers seek the sweet spot between efficacy and tolerability
The FDA is now pushing companies to find the optimal dose early in development to minimize harm.
By Kelly Bilodeau • Dec. 11, 2023